公开(公告)号：US20230139639A1

公开(公告)日：2023-05-04

申请号：US17873818

申请日：2022-07-26

申请人： BioSplice Therapeutics, Inc.

发明人： Luis A. Dellamary

IPC分类号： A61K31/444 ,  A61K9/00 ,  A61K9/10 ,  A61K31/437 ,  A61P19/02 ,  A61K47/02 ,  A61K47/38

摘要： Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

公开(公告)号：US11638758B2

公开(公告)日：2023-05-02

申请号：US17074497

申请日：2020-10-19

申请人： Mayne Pharma International Pty Ltd.

发明人： Stuart James Mudge ,  David Hayes ,  Stefan Lukas

IPC分类号： A61K31/496 ,  A61K47/38 ,  A61K9/48 ,  A61K9/00

摘要： The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections.

公开(公告)号：US20230130403A1

公开(公告)日：2023-04-27

申请号：US18066883

申请日：2022-12-15

申请人： PRIOTHERA SAS ,  PRIOTHERA LIMITED

发明人： Christoph BUCHER ,  Simone DERTSCHNIG

IPC分类号： A61K31/145 ,  A61K38/13 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/675 ,  A61K31/198 ,  A61K35/28 ,  A61P35/02 ,  A61K9/50 ,  A61K31/137 ,  A61K31/436 ,  A61K31/255 ,  A61P37/06 ,  A61K47/26 ,  A61K47/38 ,  A61K47/36 ,  A61K47/12 ,  A61K47/02 ,  A61K45/06 ,  A61K31/397 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/135

摘要： The present invention relates to S1P receptor modulators, preferably mocravimod, for use in treating patients suffering from a hematological malignancy, e.g., acute myeloid leukemia (AML), and who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The invention relates in particular to methods of treating AML in subjects undergoing HSCT, wherein said method comprises daily administering an efficient amount of S1P receptor modulator, preferably mocravimod, to said subject in need thereof, for at least 6 months, preferably at least 12 months.

公开(公告)号：US11633398B2

公开(公告)日：2023-04-25

申请号：US17888060

申请日：2022-08-15

申请人： NANOCOPOEIA, LLC

发明人： Christian F. Wertz ,  Tzehaw Chen

IPC分类号： A61K31/506 ,  A61K9/00 ,  A61K9/10 ,  A61K31/341 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K47/14 ,  A61K47/32 ,  A61K47/38

摘要： Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.

公开(公告)号：US20230121154A1

公开(公告)日：2023-04-20

申请号：US17903910

申请日：2022-09-06

申请人： University Health Network ,  Notogen, Inc.

发明人： William Mark ERWIN ,  Bjorn C. J. EEK

IPC分类号： A61K31/737 ,  A61K31/7008 ,  A61K9/00 ,  A61K47/38 ,  A61K9/08 ,  C07K14/495 ,  C07H5/06 ,  A61K47/26 ,  C08L5/08 ,  A61K47/20 ,  A61K47/36 ,  C07K14/475 ,  C07H3/02 ,  A61K38/18 ,  A61K31/726 ,  A61P19/02

摘要： There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.

公开(公告)号：US20230095356A1

公开(公告)日：2023-03-30

申请号：US17866990

申请日：2022-07-18

申请人： FUTURE MEDICINE CO., LTD.

发明人： Jae Wook YANG ,  Jee Young KIM ,  Hyuk Woo LEE ,  Chong-Woo PARK ,  Mi Ra YU ,  Ji Youn LEE ,  Bo Mi PARK

IPC分类号： A61K31/7076 ,  A61K9/00 ,  A61K47/38 ,  A61P27/02

摘要： The present disclosure relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

公开(公告)号：US11602502B2

公开(公告)日：2023-03-14

申请号：US16466975

申请日：2017-02-24

申请人： Hewlett-Packard Development Company, L.P.

发明人： Vladek Kasperchik ,  Michael G. Monroe ,  Michael J. Regan

IPC分类号： A61K9/20 ,  B33Y70/00 ,  B29C64/165 ,  A61K47/32 ,  A61K47/38 ,  B33Y10/00 ,  B33Y80/00

摘要： In an example of a three-dimensional (3D) printing method for forming a pharmaceutical tablet, build material granules are applied. Each of the build material granules includes a plurality of excipient particles, wherein at least one of the plurality of excipient particles is a latent binder. Pressure is applied to the build material granules. An activation solvent is selectively applied on at least a portion of the pressed build material granules. An active pharmaceutical ingredient formulation including an active pharmaceutical ingredient is selectively applied on the at least the portion of the pressed build material granules. The activation solvent is evaporated.

公开(公告)号：US20230070915A1

公开(公告)日：2023-03-09

申请号：US18049983

申请日：2022-10-26

申请人： VAGINAL BIOME SCIENCE, INC.

发明人： Wendy STRGAR

IPC分类号： A61K31/191 ,  A61K47/36 ,  A61K9/06 ,  A61K9/00 ,  G01N33/50 ,  A61K47/12 ,  A61K47/38 ,  A61K47/02

摘要： Vaginal lubricants that have salts which are biomatched to salts that are naturally present in the vagina facilitate intercourse without toxic effects. Topical substances that have a low buffering capacity to promote fertility by providing lubricity while minimizing disturbance to the natural pH levels present during intercourse. A low buffering capacity reduces the extent to which a product interferes with natural pH and buffering capacity of fluids that are present during intercourse.

公开(公告)号：US20230063741A1

公开(公告)日：2023-03-02

申请号：US17721970

申请日：2022-04-15

申请人： Genentech, Inc.

发明人： Justin SCHEER ,  Wenjun OUYANG ,  Richard VANDLEN ,  Philip E. HASS ,  Eric Gary STEFANICH ,  Ganesh A. KOLUMAM ,  Xiaoting WANG ,  Jed ROSS ,  Nicholas VAN BRUGGEN ,  Wyne P. LEE

IPC分类号： C07K14/54 ,  C07K16/28 ,  A61K38/20 ,  A61K47/38

摘要： The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

公开(公告)号：US20230058432A1

公开(公告)日：2023-02-23

申请号：US17794178

申请日：2021-01-22

申请人： HANMI PHARM. CO., LTD.

发明人： Bo Sik KIM ,  Hyuk Jun CHO ,  Ho Taek IM ,  Yong II KIM

IPC分类号： A61K31/4439 ,  A61K33/08 ,  A61K9/24 ,  A61K47/38 ,  A61K47/58

摘要： An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.